Secarna Addresses Undruggable Targets With Antisense Platform

 
• By Janelle Hart
  
Generate a summary of this article
Listen to this article
Beta

At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications. 

scientists gathered around a computer analyzing research
scientists gathered analyzing research • Source: Shutterstock

Founded in 2015, Secarna Pharmaceuticals entered the antisense drug discovery and development space with the goal of addressing high unmet medical needs using a never-before-seen artificial intelligence (AI)-powered platform. It is designed to select and synthesize antisense oligonucleotides (ASOs) against challenging or historically undruggable targets across indications. 

Alexander Gebauer, the company’s CEO and managing director, firmly believes that with the help of this platform, ASO therapies can...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Deal-Making

Deals Shaping The Industry, August 2024

 
• By Sabbah

<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>

Innovative Drugs: China Gains Deals, But Financing Amounts Drop

 
• By Mainbayar Badarch

China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”

Deal Volume Up, Value Down During The First Half

 
• By Joseph Haas

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals Shaping The Industry, July 2024

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.